A hunt for mountain lions along the Gila River in New Mexico led the hunter, Charles Elliott, and his guide on a chase ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Maze Therapeutics became the latest drug developer to list in New York on Friday, with its shares rising nearly 1% in their debut, giving the company a valuation of $690.37 million. The muted market ...

Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial ...

Maze Therapeutics, Inc MAZE IPO will take place January, 31 on the NASDAQ exchange under the ticker MAZE. The company is offering shares at an expected price between $15.00 and $17.00 per share with ...

Maze Therapeutics, a clinical-stage biopharmaceutical company, launched its initial public offering (IPO) today, with shares ...

Seven years ago, researchers caught an unexpected phenomenon on film: A pool of red dye that somehow 'knew' how to solve a maze filled with milk. Propelled forward by a couple drops of soap, it ...

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, ...

In this week's Turtle Bay Tuesday, the Exploration Park's Mission Aerospace exhibit invites visitors to embark on an ...

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...